A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We design, manufacture and market orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; craniomaxillofacial and thoracic (“CMFT”) products; bone cement; surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. We collaborate with healthcare professionals around the globe to advance the pace of innovation. Our products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Together with healthcare professionals, we help millions of people live better lives. In this report, “Zimmer Biomet,” “we,” “us,” “our,” “the Company” and similar words refer collectively to Zimmer Biomet Holdings, Inc. and its subsidiaries.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 8.2B | 8.2B | 7.7B | 7.4B | 6.9B | 6.8B |
| Net Income | 705M | 705M | 904M | 1.0B | 231M | 402M |
| EPS | $3.55 | $3.55 | $4.43 | $4.88 | $1.10 | $1.85 |
| Free Cash Flow | 1.5B | 1.5B | 1.3B | 1.3B | 1.2B | 1.3B |
| ROIC | 4.6% | 4.9% | 6.1% | 6.7% | 2.9% | 3.7% |
| Gross Margin | 69.7% | 69.7% | 71.5% | 71.8% | 70.9% | 71.3% |
| Debt/Equity | 0.64 | 0.64 | 0.57 | 0.53 | 0.52 | 0.69 |
| Dividends/Share | $0.96 | $0.96 | $0.96 | $0.96 | $0.96 | $0.93 |
| Operating Income | 1.1B | 1.1B | 1.3B | 1.3B | 696M | 860M |
| Operating Margin | 13.3% | 13.3% | 16.7% | 17.3% | 10.0% | 12.6% |
| ROE | 5.6% | 5.6% | 7.2% | 8.2% | 1.9% | 3.2% |
| Shares Outstanding | 199M | 199M | 204M | 210M | 210M | 217M |
ZIMMER BIOMET HOLDINGS, INC. passes 5 of 9 quality checks, suggesting mixed fundamentals.
ZIMMER BIOMET HOLDINGS, INC. trades at 26.9x trailing earnings, compared to its 15-year median P/E of 25.5x, suggesting it is currently Fair relative to its historical range. On a free-cash-flow basis, the stock trades at 12.7x vs a median of 18.0x. The company's 5-year average ROIC is 4.9% with a gross margin of 71.0%. Total shareholder yield (dividends + buybacks) is 3.6%. At current prices, the estimated annualized return to fair value is -0.0%.
ZIMMER BIOMET HOLDINGS, INC. (ZBH) has a current P/E ratio of 26.9, compared to its historical median P/E of 25.5. The stock is currently considered Fair based on its historical valuation range.
ZIMMER BIOMET HOLDINGS, INC. (ZBH) has a 5-year average return on invested capital (ROIC) of 4.9%. This is below average and may indicate limited pricing power.
ZIMMER BIOMET HOLDINGS, INC. (ZBH) has a market capitalization of $18.9B. It is classified as a large-cap stock.
Yes, ZIMMER BIOMET HOLDINGS, INC. (ZBH) pays a dividend with a trailing twelve-month yield of 1.00%. The company also returns capital through share buybacks, with a buyback yield of 2.57%.
Based on historical P/E analysis, ZIMMER BIOMET HOLDINGS, INC. (ZBH) appears fair. The current P/E of 26.9 is 5% above its historical median of 25.5. The estimated fair value CAGR (P/E method) is 18.3%.
ZIMMER BIOMET HOLDINGS, INC. (ZBH) operates in the Orthopedic, Prosthetic & Surgical Appliances & Supplies industry, within the Healthcare sector.
ZIMMER BIOMET HOLDINGS, INC. (ZBH) reported annual revenue of $8.2 billion in its most recent fiscal year, based on SEC EDGAR filings.
ZIMMER BIOMET HOLDINGS, INC. (ZBH) has a net profit margin of 8.6%. This is a modest margin.
ZIMMER BIOMET HOLDINGS, INC. (ZBH) generated $1.5 billion in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
ZIMMER BIOMET HOLDINGS, INC. (ZBH) has a debt-to-equity ratio of 0.64. This indicates moderate leverage.
ZIMMER BIOMET HOLDINGS, INC. (ZBH) reported earnings per share (EPS) of $3.55 in its most recent fiscal year.
ZIMMER BIOMET HOLDINGS, INC. (ZBH) has a return on equity (ROE) of 5.6%. This indicates moderate shareholder returns.
ZIMMER BIOMET HOLDINGS, INC. (ZBH) has a 5-year average gross margin of 71.0%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 19 years of financial data for ZIMMER BIOMET HOLDINGS, INC. (ZBH), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
ZIMMER BIOMET HOLDINGS, INC. (ZBH) has a book value per share of $63.93, based on its most recent annual SEC filing.